Dynamics of Naturally-Acquired Immunity Against SARS-CoV-2 in Children and Adolescents
暂无分享,去创建一个
T. Patalon | A. Ben-Tov | S. Gazit | Y. Saciuk | G. Perez | A. Peretz
[1] J. Stowe,et al. Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, England , 2022, medRxiv.
[2] S. Hoehl,et al. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5 , 2022, bioRxiv.
[3] V. Pitzer,et al. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study , 2022, BMJ.
[4] R. Iachan,et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[5] E. Herzel,et al. SARS-CoV-2 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: a Retrospective Cohort Study. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] V. Pitzer,et al. Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in Israel , 2022, medRxiv.
[7] S. Ladhani,et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England , 2022, The Lancet Child & Adolescent Health.
[8] Y. Maor,et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine , 2022, Nature Communications.
[9] Gheyath K Nasrallah,et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.
[10] Gheyath K Nasrallah,et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.
[11] Gheyath K Nasrallah,et al. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections , 2022, Nature communications.
[12] E. Harris,et al. Burden of SARS-CoV-2 and protection from symptomatic second infection in children , 2022, medRxiv.
[13] John Wright,et al. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection , 2021, Nature immunology.
[14] Y. Kreiss,et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.
[15] Michael I. Mandel,et al. Protection and waning of natural and hybrid COVID-19 immunity , 2021, medRxiv.
[16] S. Kannan,et al. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. , 2021, European review for medical and pharmacological sciences.
[17] D. Weinberger,et al. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. , 2021, JAMA internal medicine.
[18] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.
[19] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.
[20] N. Dean,et al. Covid-19 Vaccine Effectiveness and the Test-Negative Design , 2021, The New England journal of medicine.
[21] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[22] A. Fontanet,et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection , 2021, EBioMedicine.
[23] B. Mizrahi,et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.
[24] K. Bruxvoort,et al. Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients , 2021, Clinical Microbiology and Infection.
[25] Mattia G. Bergomi,et al. Mapping the human genetic architecture of COVID-19 , 2021, Nature.
[26] F. Krammer. A correlate of protection for SARS-CoV-2 vaccines is urgently needed , 2021, Nature Medicine.
[27] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[28] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[29] K. Mølbak,et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.
[30] G. Chodick,et al. A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report , 2021, medRxiv.
[31] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[32] A. Iwasaki. What reinfections mean for COVID-19 , 2020, The Lancet Infectious Diseases.
[33] J. Tang,et al. Setting the criteria for SARS-CoV-2 reinfection – six possible cases , 2020, Journal of Infection.
[34] G. Chodick,et al. Prevalence and Factors Associated With Resistant Hypertension in a Large Health Maintenance Organization in Israel , 2014, Hypertension.
[35] J. Coresh,et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. , 2014, JAMA.
[36] G. Chodick,et al. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. , 2011, International journal of cardiology.
[37] G. Chodick,et al. The epidemiology of diabetes in a large Israeli HMO , 2002, European Journal of Epidemiology.